Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | PGR | P06401 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3539080 | 0.85 | NPC1 (0.63) | NPC1RAB9APGRALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL7105999 | 0.83 | NPC1 (0.64) | NPC1RAB9APGRALDH1A1KMT2A | |
| SCHEMBL31488838 | 0.82 | NPC1 (0.50) | NPC1RAB9APGRALDH1A1KMT2A | |
| SCHEMBL3455697 | 0.82 | HSD11B1 (0.71) | NPC1RAB9APGRALDH1A1KMT2A | |
| SCHEMBL18992826 | 0.82 | NPC1 (1.00) | NPC1RAB9APGRALDH1A1KMT2A | |
| SCHEMBL12936225 | 0.81 | KMT2A (0.55) | ALDH1A1KMT2AMEN1HSD11B1DGAT1 | |
| SCHEMBL2253976 | 0.81 | HSD11B1 (0.66) | ALDH1A1KMT2AMEN1HSD11B1POLB | |
| SCHEMBL1548744 | 0.81 | HSD11B1 (0.66) | ALDH1A1KMT2AMEN1HSD11B1POLB | |
| SCHEMBL1397809 | 0.81 | NPC1 (0.61) | NPC1RAB9APGRALDH1A1KMT2A | |
| SCHEMBL8087323 | 0.81 | NPC1 (0.64) | NPC1RAB9APGRALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240857-B2 | Adamantane derivatives for the treatment of filovirus infection | ARISAN THERAPEUTICS INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| EP-1833806-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006064189-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| US-20030130354-A1 | 1-(Adamantyl) amidines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission | VERNALIS RESEARCH LIMITED | 2003-07-10 | — | — | US | disclosed |
| US-6500866-B1 | PROPHYLAXIS OF NEURODEGENERATIVE DISORDERS BY ADMINISTERING N-METHYL-D-ASPARTATE RECEPTOR ANTAGONIST OR PRODRUGS SUCH AS 3,5-DIMETHYL-1-ADAMANTANECARBOXIMIDAMIDE HYDROCHLORIDE | VERNALIS RESEARCH LIMITED (GB) | 2002-12-31 | — | — | US | disclosed |
| EP-1037874-B1 | 1-(ADAMANTYL)AMIDINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RES LTD (GB) | 2002-10-09 | — | — | EP | disclosed |
| EP-1037874-A1 | 1-(ADAMANTYL)AMIDINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999031051-A1 | 1-(ADAMANTYL)AMIDINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | CEREBRUS PHARMACEUTICALS LIMITED (GB) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240857-B2 | Adamantane derivatives for the treatment of filovirus infection | IFNAR1, MEP1B, MEP1A | NPC1 1346/4885RAB9A 795/4885PGR 3710/4885 |
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | NPC1 423/4885RAB9A 2923/4885PGR 2212/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | NPC1 399/4885RAB9A 2977/4885PGR 2110/4885 |
| US-20030130354-A1 | 1-(Adamantyl) amidines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission | SLC1A2, GRIN1, GRM1 | NPC1 868/4885RAB9A 774/4885PGR 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.